Madrigal Pharmaceuticals (MDGL)
(Delayed Data from NSDQ)
$244.35 USD
-1.14 (-0.46%)
Updated Jun 4, 2024 04:00 PM ET
After-Market: $244.06 -0.29 (-0.12%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
Madrigal Pharmaceuticals, Inc. [MDGL]
Reports for Purchase
Showing records 121 - 140 ( 184 total )
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Who, When, and How Much as Takeout? Increase PT to $400
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
A New Leader in NASH Emerges; Raise PT to $313 With Likely Takeout Premium
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Scores in NASH Histology, Adding a Feather in Its Cap
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - NASH Weekly: Watch Out, MDGL Could Bring Lowest Placebo Rates to the Table
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Strong Evidence Points to Another Big Win on 36-Week Biopsy Data; Raise PT to $178
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Put Hopelogy Aside, Use Data to Predict MDGL Possible Histo Outcomes
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - NASH Weekly: Our Clinicaltrials.gov tracker - Who Entered the NASH Arena?
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
1Q18: Can Also Make Money in Cancer; Affirm Buy
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - NASH Weekly: NGM Bio on Its Way to Redefine How We Think About NASH Therapies
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare: NASH Weekly: NGM Bio on Its Way to Redefine How We Think About NASH Therapies
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Here Are Our Thoughts on NGM282 Read-through to MDGL 36-week Histo Data
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - NASH Weekly Newsletter: EASL Preview Calendar
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y